PubMed Health⌕ Search

Biomedical subjects

E Bon

Publications and source records attributed to E Bon.

32 records · Page 2Linked to original sources
PubMed1996

Vitellogenin receptors during vitellogenesis in the rainbow trout Oncorhynchus mykiss.

Rainbow trout vitellogenin receptors have been characterized by ligand blotting and Scatchard analysis. Their evolution has been studied over a reproductive cycle in a broodstock of 2-year-old females. The receptors were prepared from ovarian membrane homogenates and were solubilized using n-octyl-beta-D-glucopyranoside. The visualization of the receptor by ligand blotting using 125iodine-vitellogenin after sodium dodecyl sulfate electrophoresis revealed the existence of one major binding component corresponding to a protein of 113 kDa. The Scatchard transformation of the binding data revealed a single class of binding sites with an apparent Kd of 1.8 x 10(-8) M/L. The variations of the binding characteristics (Kd and maximum binding) were investigated during vitellogenesis. This study revealed that the Kd was not affected by oocyte growth during vitellogenesis, but was highly decreased in ovulated eggs. The receptor number increased during the same period from 35 to 860 fM per oocyte, while the receptor number per mm2 of oocyte membrane surface was doubled during the same period.

Animals↗
PubMed1996

Calcification of the transverse ligament of the atlas in chondrocalcinosis: computed tomography study.

OBJECTIVE: To seek an association between articular chondrocalcinosis (AC) and calcification of the transverse ligament of the atlas (TLA), and to evaluate the frequency and the main computed tomography appearances of such calcification. METHODS: Axial computed tomography slices of the cervico-occipital hinge were performed routinely in 21 patients with AC (three men, 18 women; mean age 79 years, range 67-87) and compared with those from a control group of 21 age and gender matched patients without AC. RESULTS: Calcification of the TLA was present in 14 of the 21 patients (66%) in the AC group and in none of the 21 patients (0%) in the control group (chi 2 test: p < 0.001). Calcification was localised behind the odontoid process, inserted upon the osseous tubercles of the lateral masses of C1, and had a curvilinear profile; it varied in height (1.5 to 9 mm) and appearance (thin = < 1 mm; thick = > 1 mm) and formed either a single or a double band. CONCLUSION: This study has demonstrated a relationship between AC and calcification of the TLA. Although such calcification often remains asymptomatic (nine of 14 patients in our study), it may be associated with attacks of acute neck pain with segmentary stiffness, fever, and an increased erythrocyte sedimentation rate, sometimes revealing AC.

Aged↗
PubMed1996

Membranoproliferative glomerulonephritis, p-antineutrophil cytoplasmic antibodies, and rheumatoid arthritis. Report of a case.

Many rheumatoid arthritis patients have renal dysfunction induced either by the drugs used to treat their joint disease or by the chronic inflammation. A case of rheumatoid arthritis with p-antineutrophil cytoplasmic antibodies and mesangial glomerulonephritis that progressed to type I membranoproliferative glomerulonephritis is reported. The glomerular abnormalities were diagnosed by two renal biopsies done at a one-year interval. Reasons for the first and second renal biopsies were renal dysfunction with hematuria and impure nephrotic syndrome, respectively. Unusual features in this case include the succession of two histologic forms of glomerular disease in a patient with rheumatoid arthritis, the correlation between p-antineutrophil cytoplasmic antibody titers and activity of the renal disease. In addition, type I membranoproliferative glomerulonephritis is exceedingly rare in rheumatoid arthritis patients.

Aged↗
PubMed1996

Pamidronate infusions for the treatment of Paget's disease of bone.

Effective pamidronate dosages in Paget's disease of bone have not yet been determined. We prospectively compared two pamidronate dosages (60 mg and 120 mg) in 26 patients whose baseline alkaline phosphatase level was at least two-fold the upper limit of normal. Pamidronate was given as three-hour infusions of 60 mg each. Follow-up was two years. The two groups were comparable at baseline except for higher alkaline phosphatase and hydroxyproline levels in the group treated with 120 mg pamidronate. Efficacy on laboratory parameters was greater in the higher dosage group. Osteocalcin levels showed little change. In both dosage groups, alkaline phosphatase levels fell significantly versus baseline, and the difference persisted throughout the two-year follow-up. Urinary hydroxyproline excretion remained significantly reduced versus baseline during the first 12 months and rose subsequently. A return to normal of the two study parameters six months after treatment was associated with longer duration of the biologic treatment response. A survival curve analysis confirmed this finding and suggested that a return to normal of laboratory parameters was predictive of clinical remission. The drug was well tolerated. Adverse effects were mild and similar to those recorded during earlier studies.

Aged↗
PubMed1995

Lactose intolerance and osteoporosis in men.

Three men with osteoporotic fractures were found to have lactase deficiency and low dietary calcium intakes, decreased urinary calcium, and moderately increased serum osteocalcin and parathyroid hormone levels. Histomorphometric studies demonstrated increases in osteoid parameters and resorption surfaces. The few studies of the links between osteoporosis and lactase deficiency have yielded discordant results. A low calcium intake due to aversion to dairy products caused by the lactase deficiency may promote the development of osteoporosis.

Aged↗
PubMed1994

Renal tubular disorders and arteriopathy of the lower limbs: risk factors for osteoporosis in men?

In order to clarify the risk-factors for men with vertebral fractures due to osteoporosis, we carried out a study of 51 cases. Twenty-five percent of patients had an endocrine disorder (hyperparathyroidism, hypogonadism, hyperthyroidism) or had received corticosteroids. These patients were compared with 26 age-matched controls. Eleven patients compared with 2 of the 26 control subjects had arteriopathy of the lower limbs; 11 patients had hypercalciuria or hyperphosphaturia compared with 3 of the control subjects. Arteriopathy appears to be associated with osteoporosis in older patients (mean age 71 years), whereas renal tubular disorders were found in younger patients (mean age 45 years).

Aged↗
PubMed1994

Breast granuloma and C.R.S.T. syndrome.

One case of CRST syndrome with breast granuloma is presented. The presumed diagnosis were infectious or neoplastic diseases. High doses of corticosteroids led to improvement in breast nodules.

Breast Diseases↗
PubMed1994

[Osteocalcin and smoking].

Smoking is a risk factor for osteoporosis. Nicotine and nonnicotine tobacco smoke components have been shown to depress osteoblast activity in a number of in vitro and animal studies. To determine whether smoking is associated with depressed osteoblast activity in humans, we measured serum osteocalcin levels (using a radioimmunological method based on an antibody to human osteocalcin) in 24 male or female smokers and 24 matched nonsmokers. Overall, osteocalcin levels were significantly lower in smokers (15 +/- 6.95 ng/ml) than in nonsmokers (21.27 +/- 8.34 ng/ml) (p = 0.007). The difference between smokers and nonsmokers was significant in males (15.3 +/- 4.5 vs 23.27 +/- 9.7; p = 0.02) but not in females (16.27 +/- 8.9 vs 19.45 +/- 6.7; p = 0.2). These data suggest that smoking may induce osteoblast depression, either directly or via hormonal changes.

Adult↗
PubMed1994

[Rheumatic manifestations of chronic hepatitis C and response to the treatment with interferon alpha-2b].

Chronic hepatitis C can be responsible for a broad range of autoimmune manifestations, including cryoglobulinemia and Sjögren's syndrome. We report our experience with six patients (five women and one man; mean age 55.6 years) in whom hepatitis C was diagnosed during evaluation of joint symptoms. Polyarthralgia was the main symptom and was often accompanied with myalgia; a polyalgic syndrome was seen in some patients. Isolated cytolysis was consistently found, although, in some instances, liver enzyme elevations were moderate and postdated the onset of the clinical symptoms. The diagnosis of hepatitis C was confirmed by recombinant immunoblot assay (RIBA) in every case. The polymerase chain reaction (PCR) detected hepatitis C virus RNA in five of the six patients. Histological findings were characteristic of chronic hepatitis. All six patients had immunological test abnormalities, which included presence of rheumatoid factors (2 of 6), positive antinuclear antibodies without anti-DNA antibodies (3 of 6) and low serum complement levels (3 of 6). A cryoprecipitate was found in four of the six patients. Four patients reported symptoms of sicca syndrome and two had Chisholm grade III lesions upon examination of salivary gland biopsy specimens. Four patients were given a six-month course of interferon alpha. In three of these four patients, evaluation at the end of the treatment showed abatement or resolution of symptoms, normal liver function tests, unchanged or diminished antinuclear antibody titers, and normal serum complement levels. In the remaining patient, no changes in symptoms or transaminase levels occurred during interferon alpha treatment. In conclusion, rheumatic symptoms can be the most prominent manifestation of chronic hepatitis C.(ABSTRACT TRUNCATED AT 250 WORDS)

Autoantibodies↗
PubMed1994

[Increase of CA 19.9 in dysimmune inflammatory rheumatism. Apropos of 6 cases].

CA 19.9 is a marker for several cancers, including ductal adenocarcinomas of the pancreas. CA 19.9 elevation is rarely found in patients without benign or malignant digestive system disease. We studied serum CA 19.9 levels in patients with a variety of inflammatory joint diseases, including rheumatoid arthritis (n = 20), lupus, Sjögren's syndrome or U1RNP-associated connective tissue syndrome (Sharp's syndrome) (n = 11), dermatopolymyositis (n = 8), and giant cell arteritis or polymyalgia rheumatica (n = 8). The mean CA 19.9 level in each of these groups was not significantly different from the value seen in a group of patients with osteoporosis. Six patients had persistent marked elevation in serum CA 19.9 levels. Two had Sjögren's syndrome, two had Sharp's syndrome and two had dermatopolymyositis. None of these six patients had evidence of tumoral disease despite a follow-up of several years. Likely explanations for the CA 19.9 elevation were chronic pancreatitis in one case and lung disease in the other five. In patients with lung involvement due to inflammatory joint disease, CA 19.9 elevation may indicate severe disease and may be of use for monitoring the lung condition.

Adult↗
PubMedDate not supplied

Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.

Two recent reports of phosphate diabetes in pagetic patients prompted us to evaluate urinary phosphate and its variations under pamidronate therapy in Paget's disease of bone. We also investigated whether Paget's disease is associated with phosphate diabetes. Urinary phosphate excretion was determined in 75 pagetic patients with a mean age of 72 years. None of the patients had received treatment during the six months preceding the evaluation. The 30 patients with clinical, laboratory test, and/or roentgenographic evidence of active Paget's disease were given intravenous pamidronate in a dosage of 60 or 120 mg. The control group was composed of thirty-seven age- and sex-matched subjects selected among patients admitted for degenerative bone or joint diseases. Phosphate and calcium levels were determined in blood and urine on two consecutive days in both cases and controls. The same assays were repeated six months after pamidronate therapy in the 30 patients with active Paget's disease. Phosphate diabetes was defined as a phosphate clearance above 20 ml/mn, a rate for tubular reabsorption of phosphate above 80%, and a ratio of the maximal rate for tubular reabsorption of phosphorus over the glomerular filtration rate (TmP04/GFR) below 0.80 mmol/l. As compared with controls, untreated cases had a nonsignificant increase in phosphate clearance (16.78 +/- 10.40 ml/mn versus 14.81 +/- 7.20 ml/mn), a significant decrease in tubular reabsorption of phosphate (83.41 +/- 5.57% versus 86.70 +/- 5.30%; p < 0.05), and a nonsignificant decrease in the TmP04/GFR ratio (0.93 +/- 0.14 mmol/l versus 0.98 +/- 0.15 mmol/l).(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗